CGEM
NASDAQ · Biotechnology
Cullinan Therapeutics Inc
$17.63
+0.33 (+1.91%)
Open$16.86
Previous Close$17.30
Day High$17.97
Day Low$16.56
52W High$16.74
52W Low$5.68
Volume—
Avg Volume1.60M
Market Cap923.71M
P/E Ratio—
EPS$-3.72
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+21.7% upside
Current
$17.63
$17.63
Target
$21.45
$21.45
$16.94
$21.45 avg
$32.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |
| Rev Growth | +6.1% | +12.8% | -3.3% |
| Debt/Equity | 0.08 | 0.08 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |